Clinical Trial

A Dose Finding Study of IBI3016 in Mild to Moderate Hypertensive Patients

Name: A Dose Finding Study of IBI3016 in Mild to Moderate Hypertensive Patients — clinical trial record (NCT07352969)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

The purpose of this study is to evaluate the efficacy, safety and tolerability of IBI3016 or placebo, given subcutaneously, every 3 or 6 months, at different dose levels in patients with mild to moderate hypertension

Trial Details

NCT Number	NCT07352969
Lead Sponsor	Innovent Biologics (Suzhou) Co. Ltd.
Conditions	Hypertension
Enrollment	352 participants
Start Date	2026-02-06
Primary Completion	2029-03-27 (estimated)
Study Completion	2029-03-27 (estimated)
Updated on ClinicalTrials.gov	2026-01-20